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ABSTRACT
Understanding the molecular epidemiology of tuberculosis (TB) and mutations in genes associated with
drug resistance may contribute to the development of appropriate interventions to improve tuberculosis
control. A structured questionnaire was used to collect basic epidemiological data from 589 patients
with radiologically conﬁrmed TB in the Odessa and Nikolaev regions of the Ukraine in 2003–2004. A
non-commercial reverse hybridisation assay and DNA sequencing were used to detect mutations
associated with rifampicin and isoniazid resistance. Genotyping was performed using multilocus
variable number tandem repeat (VNTR) typing and spoligotyping. Mutations conferring rifampicin and
isoniazid resistance were detected in 32.9% and 44.0%, respectively, of 225 Mycobacterium tuberculosis
isolates from individual consecutive patients. Mutations in codon 531 and codon 315 of the rpoB and
katG genes, respectively, were predominant among drug-resistant isolates. Multidrug (MDR) resistance
rates were signiﬁcantly higher among former prison inmates compared with non-prisoners (54.8% vs.
27.3%; RR 2.01; 95% CI 1.35–2.97) and the prevalence of mutations was higher in Beijing strains sharing
the VNTR signature 223325173533424 than in other Beijing strains (71.4% vs. 45.7%; RR 1.74; 95% CI
1.17–2.57), suggesting that this group may be responsible for rapid transmission of MDR TB in the
southern Ukraine.
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INTRODUCTION
Tuberculosis (TB) remains one of the major
infectious diseases worldwide, causing 2 million
deaths annually [1]. In the Ukraine, Russia and
the majority of the other states of the former
Soviet Union (FSU), the last 15 years have been
characterised by a dramatic rise in the incidence
of TB and associated mortality in conjunction
with a converging human immunodeﬁciency
virus (HIV) ⁄AIDS epidemic [2,3]. In 2003, the
mean incidence of TB and mortality rates in the
Ukraine had risen to 77.5 ⁄ 100 000 and
21.8 ⁄ 100 000, respectively (Ukrainian TB and
Pulmonology Service, 2004 Annual Update;
http://www.ifp.kiev.ua). Southern regions, inclu-
ding Odessa and Nikolaev, are hotspots for the
TB and HIV epidemics in the Ukraine [3]. Actual
rates of both primary and acquired drug resist-
ance are unknown as this information is not
ofﬁcially registered and monitored, but limited
retrospective data for selected regions demon-
strate a substantial rise in drug resistance rates
[4].
Molecular methods of drug resistance analysis,
based on the identiﬁcation of mutations in genes
associated with the development of drug resist-
ance, offer an effective tool for drug resistance
testing because of their high sensitivity, speciﬁcity
and speed. The rapid detection of isoniazid,
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rifampicin and multidrug resistance (MDR; resist-
ance to at least isoniazid and rifampicin) is
particularly useful for effective treatment and
public health control. Several genes, including
katG, inhA, kasA and ahpC, have been associated
with resistance to isoniazid [5–7]. Elsewhere,
modiﬁcations of the katG gene were found in
c.75–90% of resistant strains, whereas mutations
in the inhA gene and the mabA-inhA regulatory
region are less common and are seen in c.5–10%
of resistant strains [6,7]. In Samara Oblast (central
Russia), 90.4% of phenotypically deﬁned isoniaz-
id-resistant strains have been shown to possess
mutations in codon 315 of the katG gene and the
regulatory region of the inhA gene [8], demon-
strating that other mechanisms (e.g., mutations in
kasA, ahpC, other codons of the katG gene, and as
yet unknown mechanisms) may be responsible
for the development of resistance in < 10% of
M. tuberculosis strains. More than 90% of rifampi-
cin-resistant strains have been shown to possess
point mutations in an 81-bp rifampicin resistance-
determining region of the rpoB gene (RRDR), but
the contribution of certain mutations in different
codons varies substantially in different countries
[5,6,9]. This may affect the performance of
molecular assays signiﬁcantly.
Recently, non-commercial molecular methods
for rifampicin and isoniazid susceptibility analy-
sis have been described, based on reverse dot-blot
hybridisation. These offer cost-effective and accu-
rate alternatives to commercial kits for research
purposes in resource-poor regions with high TB
burdens and drug resistance rates [8–11].
However, differing geographical distributions of
mutations may demand modiﬁcation of oligonu-
cleotide probe sets to achieve high sensitivity and
speciﬁcity of non-commercial assays.
The recent development of PCR-based molecu-
lar genotyping methods has led to identiﬁcation
and further differentiation of a number of clinic-
ally and epidemiologically important genetic
groups of M. tuberculosis. Development of high-
throughput multilocus techniques, using panels
of variable number tandem repeat (VNTR) loci,
has offered the possibility of rapid genotyping
with a discriminatory power comparable with
that of RFLP-IS6110 typing [12–14]. Spoligotyp-
ing, although of limited discriminative capacity
compared with RFLP-IS6110 and VNTR typing, is
particularly useful for identiﬁcation of the Beijing,
LAM, Haarlem, CAS and other common families
and lineages of M. tuberculosis [15]. Beijing family
strains have been shown to be responsible for a
number of TB outbreaks in the USA [16] and are
currently dominant across several Asian countries
and in central and north-western Russia [17–20],
whereas the LAM and T families are most
prevalent in central and south America and Africa
[15]. A signiﬁcant association of Beijing family
strains with drug resistance has been reported in
studies from Russia, the USA and Europe
[16,19,20], but this correlation is weak or absent
in several other geographical areas [21]. It is still
unclear whether there is a genetic basis for the
increased virulence and evolutionary success of
the Beijing family. The prevalence of the Beijing
and other genotypes of M. tuberculosis in the
Ukraine is unknown.
The aims of the present study were: (i) to
establish the prevalence of mutations associated
primarily with isoniazid and rifampicin resist-
ance; (ii) to deﬁne the proportion of Beijing and
other M. tuberculosis strain families circulating in
two neighbouring regions in the southern Uk-
raine using molecular epidemiological tools; and
(iii) to determine the association between geno-
types and mutations conferring rifampicin and
isoniazid resistance in M. tuberculosis strains
circulating in the southern Ukraine.
MATERIALS AND METHODS
Bacterial isolates
The study was conducted in the Odessa (1 June to 31 July 2003
and 2004) and Nikolaev (in 2003 only, because of organisa-
tional changes in patient referral patterns during 2004)
regional TB dispensaries that admit all TB cases in the regions.
All pulmonary TB patients attending the two dispensaries
during the above periods in Odessa and Nikolaev were invited
to participate in the study. According to annual regional TB
reports, the attendance of patients and the case mix (new and
chronic patients) are distributed evenly throughout the year.
The study was approved by the Committee for Biomedical
Ethics of Odessa State Medical University. Informed consent
was obtained from all patients. The overall refusal rate was
11.3%. There were no demographical or clinical differences
between recruited patients and those who refused to partici-
pate.
Bacteriological methods
Isolation and identiﬁcation of cultures were performed in the
local bacteriological laboratories of the Odessa and Nikolaev
TB dispensaries. Sputum specimens were cultured on Lowen-
stein-Jensen medium. Bacteria belonging to the M. tuberculosis
complex were identiﬁed by their macroscopic and microscopic
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appearance, growth characteristics, niacin and nitrate reduc-
tase biochemical test results, and by spacer oligonucleotide
typing (spoligotyping). A single isolate from each individual
patient was analysed.
Molecular drug resistance analysis
Crude DNA extracts were prepared by heating M. tuberculosis
cell suspensions in TE buffer (10 mM Tris-HCl, 1 mM EDTA,
pH 8.0) at 80C for 20 min [22]. Molecular drug resistance
analysis was performed at the Health Protection Agency
(HPA) Mycobacterium Reference Unit (London, UK). Rifampi-
cin and isoniazid resistance analysis was performed using
non-commercial macroarrays based on reverse hybridisation
of biotin-labelled PCR products to wild-type and mutant
oligonucleotide probes immobilised on nylon membranes, as
described previously [8,10]. The array included 11 probes for
the identiﬁcation of isolates as members of the M. tuberculosis
complex and detection of the most frequent mutations in the
rpoB, katG and inhA genes. The set of probes for the rpoB gene
comprised six probes for the detection of wild-type (i.e., no
mutation) sequences in appropriate codons, and one probe for
the detection of mutations in codon 531. The sets of probes for
the katG and inhA genes both comprised two probes indicating
either wild-type sequences or mutations in codons 315 or ) 15,
respectively. Probe sequences used were as described previ-
ously [8,10].
Isolates with mutations in the rpoB gene were considered to
be rifampicin-resistant, and mutations in the katG and ⁄ or inhA
genes were considered to be indicative of resistance to
isoniazid. Consequently, strains possessing mutations in both
rpoB and katG (or inhA) were regarded as MDR. Hybridisation,
development and analysis of membranes were performed as
described previously [8,10]. The RRDR in the rpoB gene was
sequenced in isolates designated as rifampicin-resistant in
order to identify mutations and to validate the macroarray
results. Sequencing was performed as described previously [8].
Genotyping
Spoligotyping was performed as described by Kamerbeek et al.
[23] using commercially available membranes (Isogen, Maars-
sen, The Netherlands). Multilocus VNTR analysis was per-
formed using a set of 12 mycobacterial interspersed repetitive
units (MIRU) loci and the three exact tandem repeat (ETR) loci
(A, B and C) described previously [12,13], with primer
sequences as described above [12,24]. Both multiplex and
single PCRs were performed, taking into consideration dye-
labelling and the expected length of PCR products to allow
unambiguous automated calling as described previously [25].
In all cases PCR was performed in 10-lL volumes contain-
ing 1 lL 10x PCR buffer with 1.5 mM MgCl2 (Bioline Ltd,
London, UK), 0.5 U Taq polymerase (Bioline), 0.25 lL 2 mM
dNTPs (Bioline), 0.5 lL 20 lM mix of forward and reverse
primers, 7.0 lL water and 1 lL DNA extract. Thermal cycling
was performed on a Perkin Elmer 9700 Thermocycler (PE
Applied Biosystems, Warrington, UK), with 3 min at 95C, 30
cycles of 30 s at 95C, 30 s at 60C and 60 s at 72C, followed
by 5 min at 72C and a hold at 4C. Sequencing on a Coulter
CEQ8000 DNA sequencer (Beckman Coulter, Fullerton, CA,
USA) was performed as described previously [25]. Analysis of
PCR fragment length was performed using the CEQ8000
sequencer and proprietary software (Beckman Coulter).
Results of VNTR analysis were presented as a 15-digit code.
Further analysis of genotyping data was performed using
BioNumerics software (Applied Maths, Sint-Martens-Latem,
Belgium) with categorical (for VNTR-MIRU) or Jaccard (for
spoligotyping) variable indices and the UPGMA algorithm. The
Hunter-Gaston diversity index (HGDI) was calculated as
described previously [26].
RESULTS
In total, 589 new and chronic patients with
radiologically and clinically conﬁrmed TB were
recruited (292 in 2003, with 147 in Odessa and 145
in Nikolaev, and 297 in 2004). Key baseline
epidemiological data are summarised in Table 1.
Viable M. tuberculosis cultures were isolated
from 231 patients, giving an overall isolation rate
of 39.2% (Table 1). Two-thirds (65.6%) of isolates
were cultured from patients who had never been
treated for TB. Overall, 16.0% (n = 37) of cultures
were isolated from former prison inmates, and
3.9% (n = 9) from homeless patients. Nearly all
patients were ethnic Russians or Ukrainians. All
cultures were identiﬁed as M. tuberculosis by
means of standard bacteriological and biochemi-
cal methods. Six (2.6%) isolates displayed double-
ﬁgure values of tandem repeats in several loci
following VNTR-MIRU analysis, and were there-
fore considered to be mixed cultures. These were
excluded from further analysis (leaving 225
patient isolates).
Prevalence of mutations associated with drug
resistance
The results of molecular analysis ofM. tuberculosis
isolates from patients with newly diagnosed TB
Table 1. Baseline demographical and clinical parameters
of patients
Parameters
All cases New cases
Previously
treated cases
n = 589 % n = 392 % n = 197 %
Gender
Male 465 78.9 294 75.0 171 86.8
Female 124 21.1 98 25.0 26 13.2
Age ⁄ years (median) 38 – 33 – 43 –
Residence
Homeless 13 2.2 5 1.3 8 4.1
Urban-dwellers 156 26.5 108 27.6 48 24.5
Rural 419 71.3 279 71.1 140 71.4
Previously in prison 82 13.9 33 8.4 49 25.0
Smear-positive 219 37.2 139 35 80 40.6
Culture-positivea 231 39.2 144 36.7 87 44.2
aSix mixed cultures were excluded from further molecular analysis, i.e., analysis
was performed with 225 patients.
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and those treated previously are shown in
Tables 2 and 3. The prevalence of mutations
associated with rifampicin and isoniazid resist-
ance was signiﬁcantly higher among isolates from
previously treated patients. Fifty-nine (70.2%)
isolates from patients with a history of anti-TB
treatment harboured mutations in the katG and ⁄
or inhA genes, indicating resistance to isoniazid.
The proportions of isolates with mutations asso-
ciated with rifampicin resistance were slightly
lower, comprising 16.3% and 60.7% of new
and chronic cases, respectively. Twenty (14.2%)
isolates from patients with newly diagnosed TB
had mutations in both rpoB and katG (or inhA),
and were therefore considered to be MDR. No
statistically signiﬁcant difference was observed
between the rates of mutations in strains circula-
ting in the Odessa and Nikolaev regions, or
between 2003 and 2004 (data not shown). In
contrast, the proportion of isolates from former
Table 2. Prevalence of Beijing strains and mutations associated with rifampicin and isoniazid resistance in Mycobacterium
tuberculosis isolates from patients in Nikolaev (2003) and Odessa (2003–2004) regions in the southern Ukraine
Genes affected Codons evaluated
Nikolaev (n = 42) Odessa (n = 183) All (n = 225)
New cases
Previously treated
cases Total New cases
Previously treated
cases Total New cases
Previously treated
cases Total
Rifampicin
resistancea
5 ⁄ 23 12 ⁄ 19 17 ⁄ 42 18 ⁄ 118 39 ⁄ 65 57 ⁄ 183 23 ⁄ 141 51 ⁄ 84 74 ⁄ 225
21.7% 63.2% 40.5% 15.3% 60.0% 31.1% 16.3% 60.7% 32.9%
RpoB probe 3 509–516 0 0 0 0 1 ⁄ 39 1 ⁄ 57 0 1 ⁄ 51 1 ⁄ 74
2.6% 1.8% 2.0% 1.4%
RpoB probe 6 512–519 1 ⁄ 5 1 ⁄ 12 2 ⁄ 17 3 ⁄ 18 3 ⁄ 39 6 ⁄ 57 4 ⁄ 23 4 ⁄ 51 8 ⁄ 74
20.0% 8.3% 11.8% 16.7% 7.7% 10.5% 17.4% 7.8% 10.8%
RpoB probe 9 515–522 0 0 0 0 0 0 0 0 0
RpoB probe 12 518–525 0 0 0 0 0 0 0 0 0
RpoB probe 17 523–529 3 ⁄ 5 7 ⁄ 12 10 ⁄ 17 2 ⁄ 18 3 ⁄ 39 5 ⁄ 57 5 ⁄ 23 10 ⁄ 51 15 ⁄ 74
60.0% 58.3% 58.8% 11.1% 7.7% 8.8% 21.7% 19.6% 20.3%
RpoB probe 22 528–534 1 ⁄ 5 4 ⁄ 12 5 ⁄ 17 14 ⁄ 18 33 ⁄ 39 47 ⁄ 57 15 ⁄ 23 37 ⁄ 51 52 ⁄ 74
20.0% 33.3% 29.4% 77.8% 84.6% 82.5% 65.2% 72.5% 70.3%
Isoniazid
resistance
9 ⁄ 23 12 ⁄ 19 21 ⁄ 42 31 ⁄ 118 47 ⁄ 65 78 ⁄ 183 40 ⁄ 141 59 ⁄ 84 99 ⁄ 225
39.1% 63.2% 50.0% 26.3% 72.3% 42.6% 28.4% 70.2% 44.0%
katG only 315 6 ⁄ 9 9 ⁄ 12 15 ⁄ 21 15 ⁄ 31 38 ⁄ 47 53 ⁄ 78 21 ⁄ 40 47 ⁄ 59 68 ⁄ 99
66.7% 75.0% 71.4% 48.4% 80.9% 67.9% 52.5% 79.7% 68.7%
inhA only ) 15 (regulatory
region)
1 ⁄ 9 0 1 ⁄ 21 5 ⁄ 31 0 5 ⁄ 78 6 ⁄ 40 0 6 ⁄ 99
11.1% 4.8% 16.1% 6.4% 15.0% 6.1%
Both katG
and inhA
As above 2 ⁄ 9 3 ⁄ 12 5 ⁄ 21 11 ⁄ 31 9 ⁄ 47 20 ⁄ 78 13 ⁄ 40 12 ⁄ 59 25 ⁄ 99
22.2% 25.0% 23.8% 35.5% 19.1% 25.6% 32.5% 20.3% 25.3%
MDR As above 4 ⁄ 23 11 ⁄ 19 15 ⁄ 42 16 ⁄ 118 39 ⁄ 65 55 ⁄ 183 20 ⁄ 141 50 ⁄ 84 70 ⁄ 225
17.4% 57.9% 35.7% 13.6% 60.0% 30.1% 14.2% 59.5% 31.1%
Beijing strain
prevalence
6 ⁄ 23 6 ⁄ 19 12 ⁄ 42 37 ⁄ 118 40 ⁄ 65 77 ⁄ 183 43 ⁄ 141 46 ⁄ 84 89 ⁄ 225
26.1% 31.6% 28.6% 31.4% 61.5% 42.1% 30.5% 54.8% 39.6%
aSome isolates had two codons affected in the rpoB gene.
Table 3. Association of genotypes with mutations conferring drug resistance inMycobacterium tuberculosis isolates from the
southern Ukraine
Drug resistance
pattern and mutations
Genotype
Beijing
1
223325153533424
2
223325173533424
3
Other patterns Non-Beijing
Beijing to
non-Beijing
RR (95% CI)
Subgroup 2 to all
other Beijing strains
RR (95% CI)
Mutations conferring 18 ⁄ 35 19 ⁄ 21 15 ⁄ 33 47 ⁄ 136 1.69b 1.86b
INH resistance 51.4% 90.5% 45.5% 34.6% (1.26–2.28) (1.41–2.47)
Mutations conferring 16 ⁄ 35 15 ⁄ 21 12 ⁄ 33 31 ⁄ 136 2.12 b 1.73b
RIF resistance 45.7% 71.4% 36.6% 22.8% (1.45–3.09) (1.17–2.57)
Mutations conferring 16 ⁄ 35 15 ⁄ 21 12 ⁄ 33 27 ⁄ 136 2.43 b 1.74b
multidrug resistance 45.7% 71.4% 36.6% 19.9% (1.63–3.63) (1.17–2.57)
No mutations 17 ⁄ 35 2 ⁄ 21 18 ⁄ 33 81 ⁄ 136 0.70 b 0.19 b
48.6% 9.5% 54.5% 59.6% (0.53–0.93) (0.05–0.71)
Mutations in rpoB 13 ⁄ 16a 13 ⁄ 15 a 9 ⁄ 12 a 16 ⁄ 31 a 1.58 b 1.10
gene codon 531 81.3% 86.7% 75.0% 51.6% (1.09–2.28) (0.84–1.46)
Mutations in katG 18 ⁄ 18 a 19 ⁄ 19 a 15 ⁄ 15 a 41 ⁄ 47 a 1.15 b –
gene codon 315 100% 100% 100% 87.2% (1.03–1.28) –
Mutations in inhA gene 9 ⁄ 18 a 0 ⁄ 19 a 0 ⁄ 15 a 22 ⁄ 47 a 0.37 b –
regulatory region 50.0% – – 46.8% (0.19–0.72) –
aProportion of strains resistant to corresponding drug.
bStatistically signiﬁcant difference (95% CI).
INH, isonazid; RIF, rifampicin.
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prison inmates that harboured mutations was
signiﬁcantly higher compared with that in indi-
viduals who had never been in prison (RR 1.67,
95% CI 1.15–2.41; RR 1.54, 95% CI 1.16–2.05; and
RR 1.67, 95% CI 1.15–2.41, respectively) (Fig. 1).
Sequencing of the rpoB gene RRDR in 74
isolates that displayed negative hybridisation
with one or more wild-type macroarray probes,
and were therefore considered to be rifampicin-
resistant, allowed precise identiﬁcation of codons
affected by mutations. The results of sequencing
and macroarray analysis were concordant for all
isolates. Seventy-one (95.9%) isolates possessed
mutations that have been reported previously to
be associated with high levels of rifampicin
resistance (i.e., S531L, S531W, H526Y, H526N,
H526D and D516V) [27]. Two isolates had muta-
tions associated with a low level of rifampicin
resistance (codon 514 duplication and L533P). The
mutation G523W, which has been reported to be
associated with rifampicin resistance [27], was
found in one isolate.
The diversity of genes and codons affected by
mutations associated with rifampicin and isoni-
azid resistance in M. tuberculosis strains from
Odessa and Nikolaev is summarised in Table 2.
Mutations in codon 315 of the katG gene were
found in 93 (93.9%) of 99 isolates with mutations
associated with resistance to isoniazid, and in
26.9% of these isolates, mutations in the katG gene
were combined with mutations in the regulatory
region of the inhA gene. Mutations only in the
inhA gene were seen in six isolates (6.1% of the
isolates with mutations associated with resistance
to isoniazid).
Single mutations were observed in the vast
majority (97.3%) of isolates with mutations in the
RRDR, with mutations in codon 531 dominating.
In Odessa, the proportion of mutations in codon
531 was signiﬁcantly higher than in Nikolaev
(80.7% vs. 29.4%; RR 2.7; 95% CI 1.3–5.8), while
mutations in codon 526 were more frequent in
Nikolaev (RR 11.1; 95% CI 4.8–25.8). Double
mutations in the rpoB gene (in codons 516 and
531, and in codons 526 and 531, respectively) were
detected in two isolates.
Spoligotyping
Spoligotyping of 225 M. tuberculosis isolates
yielded 21 clustered isolates (containing between
two and 75 isolates with identical proﬁles) and 52
individual patterns. The number of clustered
isolates in this panel was 173 (76.9% of all
isolates). The diversity of the spoligotyping pro-
ﬁles is summarised in Fig. 2. Eighty-nine (39.6%)
isolates with missing spacers 1–34 in the spolig-
otyping pattern were considered to belong to the
Beijing family. However, the most common
Beijing proﬁle (absence of spacers 1–34 and
presence of spacers 35–43) was seen in only 75
isolates (comprising the largest cluster of spolig-
otyping patterns), with incomplete proﬁles
observed for 14 other isolates. In these latter
isolates, spacers 37 and 35 were missing in eight
isolates and one isolate, respectively. In the
remaining ﬁve isolates, four lacked spacers 37
and 38, and one lacked spacers 38, 39 and 40.
Spoligotyping also allowed the identiﬁcation in
the Odessa and Nikolaev regions of other known
M. tuberculosis genotypes. These included the
LAM family (with the largest cluster containing
seven LAM-9 isolates), the T1 group (17 isolates)
and the Haarlem family (with the largest cluster
containing 13 isolates).
Statistical analysis demonstrated that Beijing
strains dominated in patients with a known
history of anti-TB treatment (54.8% vs. 30.5% in
new cases; RR 1.79, 95% CI 1.31–2.46), and were
also more prevalent among former prison inmates
compared with TB patients with no known
history of imprisonment (58.1% vs. 39.6%; RR
1.47, 95% CI 1.04–2.06) (Table 2 and Fig. 1).
History of imprisonment 
No history of imprisonment 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
Rifampicin
resistance
Isoniazid
resistance
MDR Beijing
Fig. 1. Prevalence of mutations associated with drug
resistance and Beijing family strains among former prison
inmates. MDR, multiple drug resistance.
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Analysis of prevalence of mutations in Beijing
and non-Beijing strains
The prevalence of mutations associated with all
types of resistance was signiﬁcantly higher among
Beijing strains, with the strongest association
being with MDR (48.3% vs. 19.8%; RR 2.43, 95%
CI 1.63–3.63) (Table 3). Drug susceptibility was
more common among non-Beijing strains (RR 1.43,
95% CI 1.08–1.90). Substantial differences were
also observed in the distribution of mutations
among Beijing and non-Beijing strains; 46.8% of
non-Beijing strains harboured mutations in the
regulatory region of inhA, whereas the prevalence
of such mutations in Beijing isolates was much
lower (RR 2.70, 95% CI 1.39–5.27). Mutations in
codon 531 of rpoB were more common among
Beijing strains (RR 1.58, 95% CI 1.09–2.28) and less
frequent among other groups of isolates. No
signiﬁcant differences in the distribution of muta-
tions in other regions of rpoB was seen.
Multilocus VNTR typing
Multilocus VNTR genotyping of 225 M. tuber-
culosis isolates using 12 MIRU and three ETR
loci yielded 121 distinct genotypes. Overall, 136
(60.4%) isolates formed 31 clusters with 90 indi-
vidual patterns (compared with 21 clusters and 52
individual isolates using spoligotyping). As
expected, the overall discriminatory ability of
VNTR genotyping for the Ukrainian isolates was
higher than that provided by spoligotyping
(HGDI 0.968 vs. 0.878). However, VNTR genotyp-
ing of 15 loci was unable to discriminate within the
Beijing family isolates; 68.6% of Beijing family
isolates comprised two large clusters formed of 35
and 21 isolates sharing the MIRU-ETR signatures
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SP4 (1) 
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SP6 (2) 
SP7 (1) 
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Fig. 2. Computer-generated image
showing 73 variants of spoligopat-
terns of Mycobacterium tuberculosis
isolates from Odessa and Nikolaev.
SP1 to SP73 are variants of spoligo-
patterns; numbers in parentheses
indicate the number of isolates shar-
ing each spoligotype.
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223325153533424 and 223325173533424, respect-
ively, supporting previous reports on the predom-
inance of these genotypes among Beijing isolates
in Russia [20,28]. Isolates with the MIRU-ETR
signature 223325173533424 were more common
among previously imprisoned patients.
Analysis of the prevalence of mutations con-
ferring drug resistance within the Beijing family
has demonstrated an uneven distribution of
mutations among different genetic subgroups.
The prevalence of mutations associated with
rifampicin and isoniazid resistance was much
higher among isolates with the VNTR signature
223325173533424 than among isolates from other
subgroups (RR 1.86, 95% CI 1.41–2.47, and RR
1.74, 95% CI 1.17–2.57, for isoniazid and rifampi-
cin resistance, respectively) (Table 3). In contrast,
the prevalence of mutations in isolates sharing
genotype 223325153533424 and other proﬁles in
Beijing family isolates was closer to that for non-
Beijing isolates, with no signiﬁcant difference
between non-Beijing isolates and Beijing isolates
not sharing the predominant signatures
223325153533424 and 223325173533424. Another
interesting phenomenon was that mutations in
the regulatory region of inhA were detected only
in eight M. tuberculosis isolates sharing proﬁle
223325153533424 (i.e., with ﬁve repeats in the
locus MIRU26) and an ‘incomplete’ spoligotyping
proﬁle with spacer 37 missing. None of the other
34 isoniazid-resistant Beijing isolates possessed
this mutation.
Results of allelic diversity analysis for 15 MIRU
and ETR loci demonstrated that the number of
allelic variants at MIRU loci varied substantially,
with the minimum variability at locus MIRU24
(two variants) and the maximum variability at
locus 10 (ten variants). The highest discriminatory
power (based on calculation of the HGDI) was
observed for locus MIRU31 (HGDI 0.695). This
locus, together with other loci displaying HGDIs
exceeding 0.6, was regarded as highly polymor-
phic on the basis of recently proposed deﬁnitions
[29]. In the panel of ETR loci, the highest discrim-
inatory power was observed for locus ETR-A
(HGDI 0.652).
DISCUSSION
This cross-sectional study is the ﬁrst survey to
address the molecular epidemiology of M. tuber-
culosis and drug-resistant M. tuberculosis strains
circulating in the Ukraine. Drug resistance was
determined by detecting mutations associated
with resistance to rifampicin and isoniazid. This
concept has proven effective for the evaluation of
drug resistance, with > 90% sensitivity for isoni-
azid and rifampicin resistance [8,10,30,31]. In
Russia, a country with the same approach to TB
treatment and the same organisational structure, a
good correlation between phenotype and the
same molecular analytical assay system has been
demonstrated, in which the system was able to
detect 95.4% of rifampicin resistance and 90.4%
of isoniazid resistance when compared with
phenotypic analysis (assuming that culture-based
drug resistance detection was deﬁnitive) [8]. As
M. tuberculosis isolates were obtained from con-
secutive patients visiting two central regional TB
dispensaries (referral sites for corresponding
regions) during deﬁned periods, it was possible
to estimate the extent of drug resistance, with
certain limitations, in the southern Ukraine. The
culture positivity rates (39.2%) in the current
study were similar to those reported from other
FSU states [32] and reﬂect the national guidelines,
i.e., diagnosis of TB is often made on the basis
solely of radiological abnormalities.
In the present study, 14.2% of isolates from
new TB patients possessed mutations associated
with MDR TB (there may be higher rates of
phenotypically deﬁned drug resistance). This is
greater than the primary MDR rates seen in other
eastern European countries (i.e., Poland, Hun-
gary, Moldova and the Baltic states) [33,34], and is
close to the rates reported for Russia and middle
Asia [19,20,35]. Estimation of current drug resist-
ance rates on the basis of molecular analysis, as
in the present study, although not validated
locally against bacteriological analysis, demon-
strated a high prevalence of rifampicin, isoniazid
and MDR strains in the southern Ukraine. The
proportion of isolates possessing mutations asso-
ciated with drug resistance was signiﬁcantly
higher among isolates from former prisoners,
suggesting that prisons play a signiﬁcant role in
sustaining the TB epidemic. The sensitivity and
speciﬁcity of the non-commercial macroarrray
technique used in the present study was con-
ﬁrmed by sequencing the relevant rpoB gene
fragment, with complete concordance of results
obtained by two methods.
In countries with a high incidence of TB, the
spectrum of mutations associated with drug
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resistance has been reported to be less diverse
than in low-incidence areas, probably because of
pronounced genetic homogeneity of strains, dom-
inance of certain genotypes, and high rates of
recent transmission [36]. In the present study, the
proportion of isolates with mutations in rpoB gene
codons (67.6%, 18.9% and 8.1% in codons 531,
526 and 516, respectively, with 4.1% of isolates
affected by mutations in other codons) was
similar to that reported for countries with
medium-to-high rifampicin resistance rates and
a substantial prevalence of Beijing family strains
[37]. Interestingly, the distribution of mutations in
rpoB gene codons was much more heterogenous
than in central Russia, where mutations in codon
531 comprised 90.1% of rifampicin-resistant iso-
lates [10], which may be explained by the pre-
ponderance of TB cases among prison inmates,
with Beijing strains being predominant. The
results of the present study provide further
evidence of a strong association between Beijing
strains with MDR and mutations in codon 531 of
the rpoB gene [38] and codon 315 of the katG gene
[39], as their prevalence was signiﬁcantly higher
among Beijing strains than among other isolates
(RR 1.88, 95% CI 1.09–2.28, for mutations in rpoB).
In the present study, 31 (31.3%) of 99 isolates
with mutations associated with isoniazid resist-
ance possessed transitions at the ) 15 position in
the regulatory region of the mabA-inhA locus in
inhA, which is higher than reported previously
[40]. Mutations in inhA were much more common
among non-Beijing isolates (46.8% vs. 17.3%; RR
2.7; 95% CI 1.39–5.27), but the reason for this is
unclear. In Beijing family isolates, mutations in
the inhA gene were limited to the separated
subgroup of nine isolates that shared a speciﬁc
spoligotype (missing spacer 37) and MIRU-ETR
signature 223325153533424. As has been argued
by Mokrousov et al. [41], spacers 37–38 may be
concealed by the presence of IS6110 insertions in
the drug resistance region, preventing primers
from binding to the corresponding targets, but an
association between these speciﬁc spoligotypes
and mutations in inhA has not been reported
previously. Spoligotyping results demonstrated
a relative diversity in the genetic structure of
M. tuberculosis strains circulating in the southern
Ukraine, with a signiﬁcant prevalence of known
M. tuberculosis families, including the LAM, T and
Haarlem families. Beijing family strains account-
ed for 39.6% of the total, which is lower than
reported previously for selected regions in Russia
[19,20]. Therefore, high drug-resistance rates
in Odessa, which is a major sea-port, resort
and university centre in the Ukraine, may be
explained not only by the high prevalence of
Beijing strains, but also by the exogenous
introduction of drug-resistant strains from high-
incidence areas because of higher migration
rates, which is in contrast to more isolated areas
such as Samara and Archangelsk in Russia.
The evaluation of the discriminatory power of
two PCR-based genotyping methods for the dif-
ferentiation ofM. tuberculosis strains circulating in
the southern Ukraine demonstrated a high dis-
criminative ability for multilocus VNTR typing,
using the panel of 12 MIRU and three ETR loci,
with an overall HGDI of 0.968. Five loci (MIRU10,
MIRU26, MIRU31, MIRU40 and ETR-A), with a
HGDI of > 0.6 and profound allelic diversity (5–10
allelic variants), were considered to be highly
discriminatory, based on the deﬁnition of Sola
et al. [29]. In comparison with the results of a
recent molecular epidemiological study in the
Samara region (personal unpublished data), in
which none of the 15 MIRU-ETR loci was iden-
tiﬁed as being highly polymorphic, it seems that
the population of M. tuberculosis strains in the
southern Ukraine is more heterogenous and less
clonal. However, the present results also support
recent evidence that the discriminatory power of
multilocus VNTR typing, using the panel of 15
loci for M. tuberculosis isolates, is compromised in
populations with a high prevalence of Beijing
family strains [28]; therefore, introduction of an
enlarged panel of highly polymorphic VNTR loci
could improve discrimination signiﬁcantly.
Further differentiation of Beijing strains using
multilocus VNTR typing allowed the identiﬁca-
tion of a number of subtypes within the Beijing
family that showed signiﬁcant disequilibrium in
distribution of mutations conferring drug resist-
ance. The prevalence of mutations in isolates
sharing genotype 223325173533424 was signiﬁ-
cantly higher than in other genotypes, suggesting
unequal association of different clones with drug
resistance within the Beijing family. This ﬁnding
may explain disagreements in published reports
with respect to the association between Beijing
strains and drug resistance in different geograph-
ical settings [19–21,42]. On the basis of a recently
reported association of strains sharing genotype
223325173533424 with imprisonment [20], sup-
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ported by the relatively higher proportion of these
strains among isolates from previously impris-
oned TB patients that was revealed by the present
study, it can be speculated that this particular
genotype may have evolutionary advantages that
may be responsible for rapid transmission of
MDR M. tuberculosis isolates in Russia and the
Ukraine. The genetic basis for this association, as
well as the factors primarily responsible for the
transmission of drug-resistant Beijing strains
among civilians and former prisoners, has yet to
be identiﬁed.
In conclusion, this ﬁrst snapshot study in the
southern Ukraine, although mainly laboratory-
focused, demonstrated a high prevalence of
mutations conferring isoniazid and rifampicin
resistance, and established relationships among
drug resistance patterns, genotypes and selected
epidemiological parameters. Clearly, there is a
need for larger prevalence studies aimed at
detecting overall drug resistance rates and major
risk-factors for TB, and at mapping drug-resistant
TB transmission. This information is crucial in
planning treatment and prophylaxis for both
immunocompetent TB patients and TB patients
with HIV co-infection, who are becoming increas-
ingly prevalent in the southern Ukraine.
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